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This is an exciting time for clinical and translational oncology.
Revolutionary advances in DNA sequencing technology have
paralleled the growth of gene- and pathway-targeted therapeu-
tics, resulting in more rational, efﬁcient, and effective drug
development pipelines centered on tumor-speciﬁc genetic
abnormalities. The need to enhance this paradigm by expand-
ing the genetic information we obtain from patients’ tumors is
self-evident. At the same time, the number of available thera-
peutic agents and combinations will continue to grow. All this
progress provides extraordinary opportunities for identifying
more and better treatment approaches for cancer patients.
Nonetheless, the parallel growth of tumor mutational informa-
tion and mutation-associated therapeutic options is outpacing
the ability of individual practitioners to reliably identify
these options. This challenge has led to the organization of
“Molecular Tumor Boards” (MTBs), groups of scientists and
clinicians who routinely review patient-level tumor genetic
information and make recommendations for therapeutic
actions. Useful as they may be, however, the MTBs generally
rely on a handful of experts whose own knowledge base is nei-
ther comprehensive nor continuously up to date. Collectively,
these facts set the stage for the study by William Kim and col-
leagues published in this issue [1], which sought to apply cogni-
tive computing to the challenge of matching individual patients
to available therapies based on tumor DNA sequencing data.
The authors’ approach involved a retrospective review of
1,018 cases that had undergone tumor sequencing. A head-to-
head and contemporaneous comparison was performed of
recommendations provided by the local University of North
Carolina (UNC) MTB with those provided by the Watson for
Genomics (WfG) cognitive computing platform. Recommended
matches could involve an approved drug and indication, an off-
label indication of an approved drug, or a clinical trial. The bot-
tom line ﬁndings of the study were that WfG identiﬁed all
“actionable” genetic mutations identiﬁed by the local MTB, but
it also identiﬁed additional actionable mutations in 323
patients. Essentially all of the WfG additional ﬁndings related
to mutations in eight genes that were not on the UNC MTB list
of actionable alterations at the time of the review, but were
deemed actionable by WfG due to recent publications and/or
recently opened clinical trials of agents in the relevant path-
ways. Notably, because of its retrospective nature, the study
could not systematically address whether the matching infor-
mation led to the recommended action, or whether the patient
beneﬁtted as a result.
How much of a step forward do these ﬁndings represent,
and what are the next steps required to further advance infor-
matics support systems such as WfG? Answering these ques-
tions ﬁrst requires being explicit about what we would like such
systems to do. As discussed in the manuscript by Kim et al., at
least three distinct components are involved in identifying
actionable alterations following initial sequence analysis. The
ﬁrst is determining whether an individual gene mutation is
actually function-altering. This determination is far from trivial
and often requires integration of protein modeling data, in vitro
data, and clinical data, to the extent that these exist for the
sequence variant in question. The present study did not speciﬁ-
cally credential the validity of variant-calling by WfG, and in any
case, none of the newly actionable determinations involved
changes in variant calling. The second component in the analy-
sis is the assignment of a given altered gene to a speciﬁc func-
tional pathway. Again, this is a complex endeavor that should
not be based simply on canonical pathway concepts, but ideally
must integrate emerging data on cross-talk and dynamic feed-
back between and within pathways [2, 3]. Finally, each available
therapeutic agent must be assigned to relevant pathway(s),
given that much of the matching does not involve the mutant
gene itself as the therapeutic target, but rather the resulting
altered pathways.
Each of these components will need to be formally vali-
dated if informatics platforms such as WfG are to prove maxi-
mally useful. Indeed, recent examples suggest that suboptimal
matching of genes to pathways and pathways to drugs may
lead to therapeutic interventions that provide little or no bene-
ﬁt to patients. For example, the SHIVA trial randomized patients
to therapy matched to the tumor molecular proﬁle versus
physician’s choice standard therapy. Fully 59% of patients (293/
496) who had complete molecular proﬁles were found to have
a therapeutic match. Unfortunately, matched therapy provided
no advantage in overall progression-free survival (PFS) com-
pared with physician’s choice therapy [4]. Among the possibil-
ities raised to explain the failure of this trial to demonstrate an
advantage for matched therapy was inaccurate or promiscuous
matching. Potentially supporting this interpretation are the
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ﬁndings of the subsequent MOSCATO trial, which compared
PFS on matched therapy with that achieved with the patient’s
prior line of therapy. Only 49% of proﬁled patients (411/843)
were assigned a match, and yet MOSCATO did demonstrate sig-
niﬁcantly longer PFS on matched compared with prior therapy
[5]. Although the design of SHIVA and MOSCATO were substan-
tially different, the overall results underscore that ﬁnding a
match is not an end unto itself, but only a means of testing the
possibility of beneﬁt.
In the study by Kim et al., 70% of patients (703/1,018) were
initially found to have one or more actionable matches by the
UNC MTB, and an additional 96 patients without a prior match
were matched to therapy by WfG. Thus, the ﬁnal proportion of
patients with a reported match in the study was a remarkably
high 78%. Furthermore, a substantial number of patients had
multiple matches, raising the issue of how effectively WfG (and
the MTB) were able to prioritize the matches. The extent to
which these relatively high rates of matching and their subse-
quent prioritization would translate into clinical efﬁcacy are
critical questions for future studies.
Even if we accept the premise that all the described analysis
steps worked optimally, the ﬁndings of Kim et al. largely dem-
onstrate that the current WfG platform can provide more up-
to-date analysis of single genes linked to sensitivity and poten-
tially to resistance. Thus, the advantage compared with the
MTB approach is a quantitative one—more efﬁcient processing
of data—rather than a qualitative one—identifying new pat-
terns that are unlikely to emerge from human-based analyses.
Clearly, however, as tumors are divided into ever-smaller
molecular subsets based on not just single mutations but
combinations thereof, the ability of humans to recognize clinically
relevant patterns will become even more limited. The same is
true for effects of new drug combinations. Thus, a truly useful
cognitive computing platform must take us out of the realm of
“known unknowns”—the availability of drugs to target the
genes and pathways whose alterations we recognize and under-
stand at some level—and into the exciting area of “unknown
unknowns”—the pathway alterations and drug effects that are
unanticipated and might only be gleaned through sophisticated
integration of large and complex datasets.
Despite these caveats, the Kim study does indeed point to
immediate and potential highly impactful applications of cogni-
tive computing platforms. Although MTBs may be up to date at
the time of initial patient presentation, most MTBs are not
equipped to systematically reanalyze patient data looking for
new matches. In contrast, this study demonstrates that such a
procedure is trivial for a computational algorithm such as WfG.
The concept that each patient’s tumor molecular proﬁle could
be continuously scanned for matches based on all available
data should be an exciting one for both patients and clinicians.
Ultimately, the growing complexity of oncology clinical and
translational research demands the integration of such infor-
matics support platforms. Accordingly, even small steps help us
envision a future in which established paradigms and new ﬁnd-
ings and opportunities can be integrated more effectively, ulti-
mately yielding a research enterprise that is far more
sophisticated than the sum of its parts.
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Editor’s Note:
See the related article, “Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing,” by
William Y. Kim et al., on page 179 of this issue.
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